Search Results 21-30 of 16292 for nivolumab

  1. Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer - Mayo Clinic

    Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Participation eligibility. Participant eligibility ...

  2. Melanoma Relatlimab Nivolumab - Mayo Clinic

    About this study. The purpose of this study is to determine whether Nivolumab in combination with Relatlimab is more effective than Nivolumab by itself in ...

  3. A Study to Test the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer - Mayo Clinic

    The purpose of this study is to determine how well cabozantinib, nivolumab, and ipilimumab work in treating patients with differentiated thyroid cancer that ...

  4. A Study to Compare Nivolumab or Brentuximab Vedotin Plus Combination Chemotherapy to Treat Patients with Newly-diagnosed Stage III-IV Classic Hodgkin Lymphoma - Mayo Clinic

    Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor ...

  5. An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer - Mayo Clinic

    An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove ...

  6. An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma - Mayo Clinic

    About this study. The purpose of this study is to determine whether an investigational immunotherapy Nivolumab, when combined with Ipilimumab, ...

  7. Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects with Nonresectable or Metastatic IDH1-Mutant Cholangiocarcinoma - Mayo Clinic

    Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects with Nonresectable or Metastatic IDH1-Mutant Cholangiocarcinoma · Overview.

  8. Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma - Mayo Clinic

    About this study. The trial is a single arm phase II clinical trial of Ipilimumab and Nivolumab in patients with resected mucosal melanoma.

  9. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study - Mayo Clinic

    ... nivolumab in each disease cohort, both across and within tumor biomarker subgroups. Participation eligibility. Participant eligibility includes age, gender ...

  10. A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients - Mayo Clinic

    About this study. The purpose of the study is to compare the efficacy and safety of nivolumab administered alone versus bevacizumab in patients diagnosed ...